Navigation Links
Is RNA Amplification Necessary for Microarrays?

RNA amplification using the Van Gelder and Eberwine technique (1) has been used extensively for target synthesis and labeling in array analysis experiments. Amplification of RNA is clearly necessary when working with limited samples (needle biopsies, LCM samples, etc.), but is it necessary when the availability of sample is not limiting? Is there additional biologically relevant information that can be obtained from array analysis using amplified RNA as a target? In this article we provide a brief synopsis of the findings of Polacek et al. (2) and Feldman et al. (3) on why amplified RNA (aRNA) might be a better choice than unamplified RNA for microarrays.

The Polacek Experiments
Polacek's group tested the fidelity of differential gene expression data using amplified RNA in a well established in vitro model of cytokine [tumor necrosis factor (TNF-α)]-stimulated human aortic endothelial cells (HAEC). 100 ng of total RNA, isolated from HAECs using a glass filter based kit, was amplified using Ambion's MessageAmp aRNA Kit, producing 4-5 g of aRNA (cRNA). 2 g of this aRNA was labeled with 33P by reverse transcription using hexanucleotide random primers; 10 g of Total RNA (unamplified) was labeled with 33P by reverse transcription using Oligo d(T)15 primers. These targets were hybridized to arrays containing 13,284 human cDNA elements.

Analysis of differential gene expression in the cells treated with TNF-α compared to untreated control cells identified 1296 genes in the amplified samples and 155 genes in the unamplified samples whose expression was affected by cytokine treatment. By comparing genes identified with probe prepared by both amplified and unamplified RNA, three categories were created: "genes common in amplified and unamplified RNA", "genes unique to amplified RNA", and "genes unique to unamplified RNA" (Figure 1). Real-time quantitative RT-PCR (qRT-PCR) analysis using SYBR Green detection of expression differences of a subset of the genes from each category was carried out. A summary of the observed results from qRT-PCR analysis and array analysis is shown in Table 1. The following conclusions were drawn from these validation studies:

(A) Because genes were identified as having differential expression with both preparations of labeled target, "common identified genes" are considered to have the highest probability of being verifiably regulated by TNF-α. In general, the ratio of gene expression with and without TNF-α treatment from amplified RNA had a closer correlation with the qRT-PCR data than ratios from unamplified RNA. 94% of the "common identified genes" show similar kinase-regulation patterns between amplified and unamplified samples.

(B) "Genes unique to amplified RNA" were ranked by P-values, and 24 genes (2.1% of the total 1,150) were selected from the entire range of P-values for validation by qRT-PCR. Similar regulation patterns between array and qRT-PCR analysis were observed in 16 of the 24 genes tested.

(C) Six from the category of "genes unique to unamplified RNA" were validated by qRT-PCR. Of these, three genes showed a similar expression ratio by qRT-PCR analysis.

Thus amplification improved the sensitivity of the array analysis, enabling the identification of biologically regulated genes that might have been missed if unamplified RNA had been used.

Figure 1. Venn Diagrams Showing the Differential Distribution of Genes Expressed With and Without TNF-α Treatment. Of the total 13,284 genes tested, 1,296 were identified from amplified RNA vs. 146 genes that are commonly represented in both samples.

Table 1. Microarray Results. This study involved the comparison of multiple replicate arrays for each condition tested: (+TNF-α and TNF-α) with use of four unamplified and five amplified RNA samples. The gene expression ratios between microarray and quantitative RT-PCR data is presented in this table.

The Feldman Experiments
Feldman et al. evaluated the fidelity of microarrays probed with amplified vs. total RNA by comparing microarray data with real-time qRT-PCR. They compared gene expression in two murine tumor cell lines (B16F10 and MC38) using mouse microarrays containing 2601 elements. In their experiments, all array hybridizations were repeated using reciprocal fluorescence to minimize the effects of labeling bias (i.e. each array was hybridized with with Cy3 labeled B16F10 RNA and Cy5 labeled MC38 RNA, and then a second identical array was hybridized with Cy5 labeled B16F10 RNA and Cy3 labeled MC38 RNA).

The following differences were observed between total RNA and amplified RNA samples:

(A) Correlation coefficients between reciprocal arrays were consistently higher with probes generated by a single or two rounds of amplification than with probes from unamplified RNA.

(B) Total RNA samples showed a higher correlation between duplicate forward or reciprocal arrays than between forward and reciprocal arrays. This was probably partially due to labeling bias. Total RNA also showed increased variability between duplicate arrays compared to amplified RNA. The authors speculate that data generated with total RNA (unamplified) may be more subject to the effects of background on the low-copy number transcripts than amplified RNA.

(C) The correlation between arrays using total RNA and amplified RNA was found to be similar to duplicate arrays probed with total RNA. This observation corroborates the finding that amplification does not significantly bias the gene expression data.

The authors further evaluated wh ether the individual genes that were differentially expressed in amplified samples would have been identified as such using total RNA. For this experiment, the number of "outliers" defined by authors as "A gene with expression ratios of greater than or equal to 2.0 or less than or equal to 0.5 in two reciprocal microarray analysis" identified using total RNA or amplified RNA (one or two rounds of amplification) were compared. The amplified samples identified approximately 80% of the genes selected as outliers with total RNA, with an 80% concordance between target made by one and two rounds of amplification. Thus amplification yielded approximately 2 times more outliers than total RNA, with 80% of these showing similar trends in expression between amplified and total RNA samples. Validation of the "outliers" between total RNA and amplified RNA was carried out using real-time PCR analysis. The PCR data suggested that the majority of outliers identified using amplified RNA are valid. Thus Feldman et al. also conclude that all RNA samples should undergo at least one round of amplification to maximize the quality of array data for detection of differentially expressed genes.

SYBR Green is a registered trademark of Molecular Probes, Inc.
Cy is a trademark of Amersham Biosciences.

back to top

Ordering Information
Cat # Product Name Size 1750 MessageAmp aRNA Kit 20 rxns 1751 MessageAmp II aRNA Amplification Kit 20 rxns


Page: All 1 2 3 4 5 6

Related biology technology :

1. prostar RT-PCR Systems for Robust High-Fidelity RNA Amplification
2. Simple Purification of DNA from Plasmid Minipreps, PCR Amplifications and Agarose Gels
3. Greater Amplification Specificity with New Hot Start PCR Enzyme
4. Enhanced Amplification of Long Targets with PfuTurbo DNA Polymerase
5. Optimizing pfuturbo DNA Polymerase Amplification Reactions with Perfect Match PCR Enhancer
6. Improve Amplification Specificity with Hot Start PCR Enzyme
7. Amplification of the amoA Gene of Nitrosococcus oceani Bacteria Using Eppendorf MasterTaq
8. Amplification of Mouse cDNAs for Microarrays Using the Eppendorf MasterTaq Kit
9. Optimizing the Direct Amplification of Missing cDNA 5 Ends Using the Eppendorf Mastercycler gradient
10. Optimizing DNA Amplification Protocols using the Eppendorf Mastercycler
11. Amplification of Epstein-Barr Virus Exon C with Difficult Primers Using Eppendorf Mastercycler gradient
Post Your Comments:

(Date:3/22/2017)... Milwaukee, WI (PRWEB) , ... March 22, 2017 , ... ... federal scientific research agencies as outlined in the Administration’s recently published fiscal year 2018 ... for the National Institutes of Health (NIH) by $5.8 billion or roughly 20% of ...
(Date:3/22/2017)... Mass. , March 22, 2017  RXi ... developing innovative therapeutics that address significant unmet medical ... RXi,s Chief Business Officer, will present at the ... forum will provide a platform to present to ... institutes, leading pharmaceutical and biotech companies as well ...
(Date:3/20/2017)... City, NY (PRWEB) , ... March 20, 2017 ... ... and equipment for pharmaceutical and biotech companies, recently announced it will debut a ... in New York City. The intelliVessel is controlled by a touch screen panel ...
(Date:3/20/2017)... ... March 20, 2017 , ... The fourth annual Hackaday ... to make an extraordinary impact on peoples’ lives, launches today. Sponsored by Digi-Key ... 5 weeks and awards thousands in cash prizes to engineers, inventors and tinkerers who ...
Breaking Biology Technology:
(Date:2/28/2017)... Feb. 28, 2017   Acuant , a leading ... announces significant enhancements to new and core technologies building ... products include mobile and desktop Acuant FRM TM ... - a real time manual review of identity documents ... provides the fastest and most accurate capture software to ...
(Date:2/28/2017)... , Spanien, 27. Februar 2017  EyeLock LLC, ein ... wird seine erstklassige biometrische Lösung zur Iris-Erkennung ... mit X16 LTE auf dem Mobile World ... am Qualcomm-Stand in Halle 3, Stand 3E10, ... die Sicherheitsplattform Qualcomm Haven™ – eine Kombination ...
(Date:2/26/2017)... -- Securus Technologies, a leading provider of civil and ... corrections and monitoring, announces the appointment of a ... often, too many offenders return to jail or ... to tackle this ongoing problem and improve the ... significant steps are underway, Securus continues to invest ...
Breaking Biology News(10 mins):